USD
$0.00
(0.00%
)At Close (As of Sep 8, 2025)
$36.27M
Market Cap
-
P/E Ratio
-0.7
EPS
$1.70
52 Week High
$0.61
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $6.3M |
Total Revenue | $6.3M |
Cost Of Revenue | $1.6M |
Costof Goods And Services Sold | $1.6M |
Operating Income | -$61M |
Selling General And Administrative | $25M |
Research And Development | $41M |
Operating Expenses | $67M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | $100K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.6M |
Income Before Tax | -$58M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$58M |
Comprehensive Income Net Of Tax | - |
Ebit | -$60M |
Ebitda | -$58M |
Net Income | -$58M |
Field | Value (USD) |
---|---|
Total Assets | $71M |
Total Current Assets | $60M |
Cash And Cash Equivalents At Carrying Value | $55M |
Cash And Short Term Investments | $55M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $11M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $4.9M |
Other Non Current Assets | - |
Total Liabilities | $53M |
Total Current Liabilities | $27M |
Current Accounts Payable | $2.6M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.2M |
Total Non Current Liabilities | $26M |
Capital Lease Obligations | $8.1M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $8.1M |
Other Current Liabilities | $10M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $18M |
Treasury Stock | - |
Retained Earnings | -$384M |
Common Stock | $5K |
Common Stock Shares Outstanding | $54M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$18M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $1.6M |
Capital Expenditures | $36K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$36K |
Cashflow From Financing | $29M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$58M |
Field | Value (USD) |
---|---|
Gross Profit | $6.3M |
Total Revenue | $6.3M |
Cost Of Revenue | $1.6M |
Costof Goods And Services Sold | $1.6M |
Operating Income | -$61M |
Selling General And Administrative | $25M |
Research And Development | $41M |
Operating Expenses | $67M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | $100K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.6M |
Income Before Tax | -$58M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$58M |
Comprehensive Income Net Of Tax | - |
Ebit | -$60M |
Ebitda | -$58M |
Net Income | -$58M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune systems of cancer patients. The company is headquartered in Waltham, Massachusetts.